Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 486

1.

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.

Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS.

Clin Cancer Res. 2019 Aug 9. doi: 10.1158/1078-0432.CCR-18-4159. [Epub ahead of print]

PMID:
31399473
2.

Pharmacogenomics.

Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL.

Lancet. 2019 Aug 10;394(10197):521-532. doi: 10.1016/S0140-6736(19)31276-0. Epub 2019 Aug 5. Review.

PMID:
31395440
3.

Opportunities, resources, and techniques for implementing genomics in clinical care.

Manolio TA, Rowley R, Williams MS, Roden D, Ginsburg GS, Bult C, Chisholm RL, Deverka PA, McLeod HL, Mensah GA, Relling MV, Rodriguez LL, Tamburro C, Green ED.

Lancet. 2019 Aug 10;394(10197):511-520. doi: 10.1016/S0140-6736(19)31140-7. Epub 2019 Aug 5. Review.

PMID:
31395439
4.

Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation.

Hicks JK, McLeod HL.

Biomark Med. 2019 Aug;13(12):987-990. doi: 10.2217/bmm-2019-0228. Epub 2019 Aug 6. No abstract available.

5.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer.

Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, Innocenti F, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K.

Cancer Causes Control. 2019 Jul;30(7):757-765. doi: 10.1007/s10552-019-01183-1. Epub 2019 May 18.

PMID:
31104167
6.

An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).

Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K.

Pharmacogenet Genomics. 2019 Aug;29(6):123-131. doi: 10.1097/FPC.0000000000000375.

PMID:
30889042
7.

NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.

Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Lavoie Smith E, McCaskill Stevens W, Janelsins MC.

J Natl Cancer Inst. 2019 Jan 31. doi: 10.1093/jnci/djz011. [Epub ahead of print]

PMID:
30715378
8.

β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms.

Xie WY, He RH, Zhang J, He YJ, Wan Z, Zhou CF, Tang YJ, Li Z, Mcleod HL, Liu J.

Oncol Rep. 2019 Jan;41(1):341-350. doi: 10.3892/or.2018.6830. Epub 2018 Oct 29.

PMID:
30542705
9.

Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer.

Liao P, Li W, Liu R, Teer JK, Xu B, Zhang W, Li X, Mcleod HL, He Y.

Onco Targets Ther. 2018 Oct 15;11:6969-6980. doi: 10.2147/OTT.S173934. eCollection 2018.

10.

Genetic variation determines VEGF-A plasma levels in cancer patients.

Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K.

Sci Rep. 2018 Nov 5;8(1):16332. doi: 10.1038/s41598-018-34506-4.

11.

The influence of Neanderthal alleles on cytotoxic response.

Akhtari FS, Havener TM, Fukudo M, Jack JR, McLeod HL, Wiltshire T, Motsinger-Reif AA.

PeerJ. 2018 Oct 23;6:e5691. doi: 10.7717/peerj.5691. eCollection 2018.

12.

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL.

Clin Pharmacol Ther. 2019 Mar;105(3):738-745. doi: 10.1002/cpt.1241. Epub 2018 Nov 1.

13.

Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.

Ramamoorthy A, Knepper TC, Merenda C, Mendoza M, McLeod HL, Bull J, Zhang L, Pacanowski M.

Clin Pharmacol Ther. 2018 Nov;104(5):940-948. doi: 10.1002/cpt.1180. Epub 2018 Sep 14.

14.

The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer.

Tang L, Hu H, He Y, Mcleod HL, Xiao D, Chen P, Shen L, Zeng S, Yin X, Ge J, Li L, Ma J, Chen Z, Huang J.

J Cancer. 2018 Aug 6;9(17):3109-3116. doi: 10.7150/jca.25235. eCollection 2018.

15.

Clinical and pharmacogenetics associated with recovery time from general anesthesia.

Xie S, Ma W, Shen M, Guo Q, Wang E, Huang C, Wang Y, Chen X, Liu Z, Zhang W, McLeod HL, He Y.

Pharmacogenomics. 2018 Sep 1;19(14):1111-1123. doi: 10.2217/pgs-2018-0085. Epub 2018 Aug 23.

PMID:
30136624
16.

Geographic variation in molecular subtype for gastric adenocarcinoma.

Liao P, Jia F, Teer JK, Knepper TC, Zhou HH, He YJ, McLeod HL.

Gut. 2019 Jul;68(7):1340-1341. doi: 10.1136/gutjnl-2018-316605. Epub 2018 Jun 29. No abstract available.

PMID:
29960981
17.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5.

PMID:
29871907
18.

When will clinical trials finally reflect diversity?

Knepper TC, McLeod HL.

Nature. 2018 May;557(7704):157-159. doi: 10.1038/d41586-018-05049-5. No abstract available.

PMID:
29743700
19.

Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.

Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators; ACCORD/ACCORDion Investigators.

Diabetes. 2018 Jul;67(7):1428-1440. doi: 10.2337/db17-1164. Epub 2018 Apr 12.

20.

Value of Supportive Care Pharmacogenomics in Oncology Practice.

Patel JN, Wiebe LA, Dunnenberger HM, McLeod HL.

Oncologist. 2018 Aug;23(8):956-964. doi: 10.1634/theoncologist.2017-0599. Epub 2018 Apr 5. Review.

21.

Avoidance of Severe Cutaneous Adverse Drug Events as a First Step in Precision Neurology.

He Y, Seminario-Vidal L, McLeod HL.

JAMA Neurol. 2018 Jul 1;75(7):793-795. doi: 10.1001/jamaneurol.2018.0001. No abstract available.

PMID:
29610896
22.

Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.

Wang W, Wang K, Chen Z, Chen L, Guo W, Liao P, Rotroff D, Knepper TC, Liu Z, Zhang W, Mcleod HL, He Y.

Oncotarget. 2018 Jan 6;9(15):12164-12173. doi: 10.18632/oncotarget.24037. eCollection 2018 Feb 23.

23.

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.

Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, Lin HY, Hoogland AI, Gonzalez BD, Nelson AM, Kinney AY, Fischer SM, Li D, Jacobsen PB, McLeod HL, Jim HSL.

Support Care Cancer. 2018 Aug;26(8):2911-2918. doi: 10.1007/s00520-018-4120-6. Epub 2018 Mar 15.

24.

Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.

Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH.

Contemp Clin Trials. 2018 May;68:7-13. doi: 10.1016/j.cct.2018.03.001. Epub 2018 Mar 10.

25.

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.

Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez LL, Aronson S, Cavallari LH, Denny JC, Dressler LG, Johnson JA, Klein TE, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV.

Clin Pharmacol Ther. 2018 May;103(5):778-786. doi: 10.1002/cpt.1048. Epub 2018 Mar 30. Review.

26.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

27.

Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.

Gillis NK, Rotroff DM, Mesa TE, Yao J, Chen Z, Carulli MA, Yoder SJ, Walko CM, Teer JK, McLeod HL.

Oncotarget. 2017 Dec 4;8(70):115114-115127. doi: 10.18632/oncotarget.22914. eCollection 2017 Dec 29.

28.

The pharmacogenetics of medications used in general anesthesia.

Xie S, Ma W, Guo Q, Liu J, Li W, McLeod HL, He Y.

Pharmacogenomics. 2018 Feb;19(3):285-298. doi: 10.2217/pgs-2017-0168. Epub 2018 Jan 10. Review.

PMID:
29318929
29.

miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer.

Huang J, He Y, Mcleod HL, Xie Y, Xiao D, Hu H, Chen P, Shen L, Zeng S, Yin X, Ge J, Li L, Tang L, Ma J, Chen Z.

BMC Cancer. 2017 Dec 22;17(1):886. doi: 10.1186/s12885-017-3875-3.

30.

Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance.

Jack J, Small GW, Brown CC, Havener TM, McLeod HL, Motsinger-Reif AA, Richards KL.

Pharmacogenomics J. 2018 May 22;18(3):467-473. doi: 10.1038/tpj.2017.41. Epub 2017 Dec 5.

31.

The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.

Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O'Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK.

Cancer Chemother Pharmacol. 2018 Feb;81(2):413-417. doi: 10.1007/s00280-017-3487-2. Epub 2017 Nov 20.

32.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M.

Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.

33.

Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.

Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung WH, Dalton AD, Hung SI, Lee MTM, Leeder JS, Lertora JJL, Mahasirimongkol S, McLeod HL, Mockenhaupt M, Pacanowski M, Phillips EJ, Pinheiro S, Pirmohamed M, Sung C, Suwankesawong W, Trepanier L, Tumminia SJ, Veenstra D, Yuliwulandari R, Shear NH.

Clin Pharmacol Ther. 2018 Mar;103(3):390-394. doi: 10.1002/cpt.890. Epub 2017 Nov 6. Review.

34.

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.

Marcath LA, Deal AM, Van Wieren E, Danko W, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL.

Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311.

35.

Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat.

Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S.

J Adolesc Young Adult Oncol. 2017 Dec;6(4):503-511. doi: 10.1089/jayao.2017.0051. Epub 2017 Aug 4. No abstract available.

36.

Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way.

Wang W, Liu J, He Y, McLeod HL.

Pharmacogenomics. 2017 Aug;18(13):1299-1304. doi: 10.2217/pgs-2017-0053. Epub 2017 Jul 26. Review.

PMID:
28745931
37.

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.

Clin Pharmacol Ther. 2018 Apr;103(4):712-721. doi: 10.1002/cpt.798. Epub 2017 Nov 3.

38.

EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients.

Shen H, Zhong M, Wang W, Liao P, Yin X, Rotroff D, Knepper TC, Mcleod HL, Zhou C, Xie S, Li W, Xu B, He Y.

Clin Chim Acta. 2017 Aug;471:216-221. doi: 10.1016/j.cca.2017.06.006. Epub 2017 Jun 7.

PMID:
28601671
39.

Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.

Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL.

J Invest Dermatol. 2017 Sep;137(9):2021-2023. doi: 10.1016/j.jid.2017.05.010. Epub 2017 May 23. Review. No abstract available.

40.

Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial.

Marvel SW, Rotroff DM, Wagner MJ, Buse JB, Havener TM, McLeod HL, Motsinger-Reif AA; The ACCORD/ACCORDion Investigators.

PeerJ. 2017 May 2;5:e3187. doi: 10.7717/peerj.3187. eCollection 2017.

41.

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.

Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS.

JAMA Dermatol. 2017 Jun 1;153(6):607-609. doi: 10.1001/jamadermatol.2017.0187. No abstract available.

PMID:
28384659
42.

Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research.

Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, Worthey E, Chisholm RL, Green ED, Jacob HJ, McLeod HL, Roden D, Rodriguez LL, Williams MS, Cooper GM, Cox NJ, Herman GE, Kingsmore S, Lo C, Lutz C, MacRae CA, Nussbaum RL, Ordovas JM, Ramos EM, Robinson PN, Rubinstein WS, Seidman C, Stranger BE, Wang H, Westerfield M, Bult C.

Cell. 2017 Mar 23;169(1):6-12. doi: 10.1016/j.cell.2017.03.005.

43.

Strategies for integrating personalized medicine into healthcare practice.

Pritchard DE, Moeckel F, Villa MS, Housman LT, McCarty CA, McLeod HL.

Per Med. 2017 Mar;14(2):141-152. doi: 10.2217/pme-2016-0064. Epub 2017 Jan 19.

44.

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.

Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.

Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.

PMID:
28235141
45.

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.

Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM.

Oncologist. 2017 Feb;22(2):144-151. doi: 10.1634/theoncologist.2016-0195. Epub 2017 Feb 8.

46.

Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.

Walko CM, Aubert RE, La-Beck NM, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL.

Oncologist. 2017 Feb;22(2):208-212. doi: 10.1634/theoncologist.2016-0233. Epub 2017 Feb 6.

47.

American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data.

Jim HS, McLeod HL.

J Clin Oncol. 2017 Apr 1;35(10):1133-1134. doi: 10.1200/JCO.2016.69.2079. Epub 2017 Feb 6. No abstract available.

PMID:
28165908
48.

Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.

Jia F, Teer JK, Knepper TC, Lee JK, Zhou HH, He YJ, McLeod HL.

Mol Diagn Ther. 2017 Apr;21(2):179-185. doi: 10.1007/s40291-016-0250-z.

49.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ.

Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18. Erratum in: Clin Pharmacol Ther. 2018 Feb;103(2):349.

50.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582

Supplemental Content

Loading ...
Support Center